Mindray Medical Investment Quality Review (300760.SZ)

Quality score: 83/100 Valuation position: current price/base FV 1.69 Final signal: WATCHLIST

Core Conclusion

Mindray Medical is WATCHLIST. The business scores well at 83/100, but current price of CNY158.88 is materially above base FV of CNY94.02. Conservative/base/optimistic FV is CNY72.28/CNY94.02/CNY124.26.

Business And Quality

Five-year revenue CAGR is 7.1%, and latest-year FCF is CNY8.11bn. The quality score reflects medical-device franchise strength, cash generation, and net cash, while policy, procurement, and margin risks prevent an upgrade at this price.

Financial Audit

The review uses fiscal 2021-2025 in CNY and a 1.7% CNY 10Y government-bond yield dated 2026-07-31. Five-year FCF/Net Income is 0.91 and OCF/Net Income is 1.12. Latest net cash is CNY17.34bn.

Valuation

The model uses normalized FCF plus balance-sheet adjustments. Price/base FV of 1.69 fails the 0.70 buy gate and does not provide downside protection despite the high-quality score.

Buy And Monitor

Current action is watchlist. Upgrade requires price/base FV below 0.70, quality score at least 75, and evidence that procurement and growth risks are over-discounted. Track revenue trend, FCF/Net Income, ROIC, net cash/debt, dividends, buybacks, and governance disclosure.

Risks

Risks include centralized procurement pressure, hospital capex cycles, overseas execution, gross-margin pressure, R&D productivity, and shareholder-return discipline.

Sources

Sources are public quote and financial data platforms, company filings or IR, ChinaBond for the CNY risk-free rate, and public FX data where applicable. Research only, not personalized investment advice.